Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $6.27M | $5.13M | $4.73M | $4.22M | $3.87M | $3.21M | $4.44M | $4.36M |
| Selling, general and administrative | $4.36M | $4.12M | $3.53M | $2.87M | $3.00M | $2.86M | $2.48M | $2.97M |
| Operating expenses | $10.63M | $9.25M | $8.26M | $7.08M | $6.87M | $6.06M | $6.92M | $7.33M |
| Operating income | −$10.63M | −$9.25M | −$8.26M | −$7.08M | −$6.87M | −$6.06M | −$6.92M | −$7.33M |
| EBITDA | −$10.63M | −$9.25M | −$8.26M | −$7.08M | −$6.87M | −$6.06M | −$6.92M | −$7.33M |
| Interest income | $1.02M | $845.00K | $597.00K | $292.00K | $272.00K | $250.00K | $181.00K | $221.00K |
| Income before taxes | −$9.61M | −$8.41M | −$7.66M | −$6.79M | −$6.60M | −$5.81M | −$6.74M | −$7.11M |
| Net income | −$9.61M | −$8.41M | −$7.66M | −$6.79M | −$6.60M | −$5.81M | −$6.74M | −$7.11M |
| EPS, basic | −$0.05 | −$0.05 | −$0.05 | −$0.06 | −$0.07 | −$0.07 | −$0.09 | −$0.10 |
| EPS, diluted | −$0.05 | −$0.05 | −$0.05 | −$0.06 | −$0.07 | −$0.07 | −$0.09 | −$0.10 |
| Diluted shares | 189.18M | 172.48M | 141.49M | 108.40M | 98.56M | 87.76M | 74.11M | 68.25M |
Figures describe SELLAS Life Sciences shares, not any token. As of Aug 11, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.